Rasburicase Injection Suppliers & Bulk Manufacturers
Available Forms: IV infusion
Available Strengths: 7.5 mg/15 mL vial
Reference Brands: Elitek(US)
Category:
Oncology Cancer Care
Rasburicase Injection 7.5 mg/15 mL is used to treat tumor lysis syndrome (TLS) in cancer patients, particularly those with leukemia and lymphoma. Available in both the U.S. and EU, it helps prevent kidney damage by converting uric acid into allantoin. Essential for oncology B2B distribution.
Rasburicase Injection is available in IV infusion
and strengths such as 7.5 mg/15 mL vial.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Rasburicase Injection is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Rasburicase Injection can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Rasburicase Injection 7.5 mg/15 mL is a critical treatment for tumor lysis syndrome (TLS), commonly associated with hematologic cancers like leukemia and lymphoma. By converting uric acid into allantoin, Rasburicase reduces the risk of kidney damage caused by high uric acid levels. Approved in both the U.S. and EU, Elitek (brand name in the U.S.) is supplied as a sterile IV solution for infusion. Rasburicase is essential for B2B pharmaceutical distribution, supporting oncology care centers, hospitals, and clinics with essential treatment for high-risk cancer patients undergoing chemotherapy.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing